Chronic Renal Failure
Conditions
Keywords
Peritoneal Dialysis, Biocompatible dialysis solution, Hydration status, Residual renal function, Body composition monitor, Bioimpedance spectroscopy, Cancer antigen 125
Brief summary
To investigate the biocompatibility of the peritoneal dialysis (PD) solution balance in comparison to the conventional PD solution in APD(automated peritoneal dialysis) patients using the APD cycler sleep•safe.
Detailed description
Equivalence of the investigational PD solution balance regarding fluid status compared to the conventional PD solution. Effects of balance on inflammation and systemic advanced glycation end products formation. Effects of balance on peritoneal and total urea clearance, on peritoneal and total creatinine clearance and on ultrafiltration, on residual diuresis and on cholesterol levels. Safety of the investigational PD solution balance and the conventional PD solution as a control drug. The mesothelial cell mass assessed by Cancer Antigen 125 is affected by the use of the type of PD solution in APD patients using sleep•safe. Treating patients with the PD solution balance leads to not more than 1 litre difference in hydration in comparison to the conventional PD solution which is considered as clinically not relevant regarding blood pressure.
Interventions
DRUGSolution B (balance PD solution)
balance 1.5% glucose, solution for peritoneal dialysis; balance 2.3% glucose, solution for peritoneal dialysis; balance 4.25% glucose, solution for peritoneal dialysis, each with 1.25 mmol/l or 1.75 mmol/l calcium
DRUGSolution A (conventional PD solution)
Solutions for peritoneal dialysis: CAPD 2 (1.5% glucose, 1.75mmmol/l calcium), CAPD 3 (4.25 % glucose, 1.75mmmol/l calcium), CAPD 4 (2.3% glucose, 1.75mmmol/l calcium), CAPD 17 (1.5% glucose, 1.25mmmol/l calcium), CAPD 18 (4.25% glucose, 1.25mmmol/l calcium) and CAPD 19 (2.3% glucose, 1.25mmmol/l calcium)
Sponsors
Fresenius Medical Care Deutschland GmbH
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* APD patient ≥ 18 years * Prevalent patient with at least 3 months experience on APD prior to inclusion * Patient is trained on and being treated with the sleep•safe APD cycler * Patient treated on APD exclusively with registered conventional PD solutions CAPD 2, CAPD 3, CAPD 4, CAPD 17, CAPD 18 or CAPD 19 for at least 8 weeks prior to inclusion * Patient is on stable diuretic treatment e.g no change in diuretic treatment within the last 30 days prior to inclusion * Informed consent signed and dated by study patient and investigator/authorised physician * Ability to understand the nature and requirements of the study
Exclusion criteria
* Peritonitis treatment £ 4 weeks preceding inclusion * APD patients treated with IPD modality (intermittent peritoneal dialysis) * Malignant disease without remission * Patients with artificial joints, amputations, stents, or pacemaker * Patients with congestive heart failure or coronary artery disease NYHA (New York Heart Association) III and higher * Active HBV (hepatitis B virus)or HCV(hepatitis C virus)infection- HIV positive * Participation in an interventional clinical study during the preceding 30 days * Any condition which could interfere with the patient's ability to comply with the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CA 125 (cancer antigen 125) appearance rate in the 24 hours effluent and estimated hydration | 16 weeks | The appearance rate is defined as the sum of the amount of CA125 determined in each outflow bag (concentration of CA125 in outflow multiplied with outflow volume) divided by the real cumulative dwell time of all dwells performed on the day of the 24-hour dialysate collection. |
Countries
Poland, Spain
Outcome results
None listed